Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII

NCT07326566 is registered in ClinicalTrials.gov with Black Diamond Therapeutics, Inc. as lead sponsor.

NCT NCT07326566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07326566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII
Lead sponsor
Black Diamond Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 5, 2026
Completion date
March 31, 2029
Enrollment
162 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, central nervous system diseases, gbm, glioblastoma (gbm), glioblastoma multiforme (gbm), glioma, newly diagnosed glioblastoma